Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer.

Authors:
Baudoux N; Friedlaender A; Addeo A.

Journal:
Clin Med Insights Oncol

Publication Year: 2023

DOI:
10.1177/11795549231152948

PMCID:
PMC9932776

PMID:
36818454

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Clin Med Insights Oncol

Abbreviation: Clin Med Insights Oncol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Characterization and Survival Benefit of Drug Approvals for Metastatic Prostate Cancer, 2004 to 202…
Benjamin DJ; Rezazadeh Kalebasty A. (2024) - Transparency Score: 3/6
Copper Chaperone for Superoxide Dismutase Subtypes as a Prognostic Marker in Luminal B Breast Cance…
Li Y; Du W; Yang R and 3 more (2024) - Transparency Score: 3/6
Peripheral Blood CD8<sup>+</sup> CD28<sup>+</sup> T Cells as an Independent Predictor of Treatment …
Wang S; Mu X; Wang X and 3 more (2024) - Transparency Score: 3/6
Prognostic Significance of the Cachexia Index in Patients with Non-Small-Cell Lung Cancer and Brain…
Xu H; Zhang B; Zhang Y and 5 more (2024) - Transparency Score: 3/6
Risk Factors for Distant Metastasis in T3 T4 Rectal Cancer.
Tang C; Xu J; Lin M and 5 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: NB reports no conflict of interest. AF received, outside of the present work, personal fees from Bristol Myers Squibb, Roche Holdings AG, Pfizer, Astellas, and Merck Sharp & Dohme. AA reports Consulting or advisory role from BMS, AstraZeneca, Boehringer Ingelheim, Roche, MSD, Pfizer, Eli Lilly, and Astellas, and Speaker bureau from Eli Lilly and AstraZeneca."

Evidence found in paper:

"Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025